Welcome!

News Feed Item

Resmed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2014

SAN DIEGO, April 23, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2014.  Revenue for the quarter was $397.8 million, a 4 percent increase (a 3 percent increase on a constant currency basis) over the quarter ended March 31, 2013.  Net income was $90.0 million, an increase of 6 percent compared to the quarter ended March 31, 2013.  Diluted earnings per share for the quarter were $0.63, an increase of 9 percent compared to the quarter ended March 31, 2013.  

ResMed Inc. logo

Selling, general and administrative expenses were $115.1 million for the quarter, an increase of 5 percent (a 7 percent increase on a constant currency basis) over the quarter ended March 31, 2013.  SG&A costs were 28.9 percent of revenue in the quarter, compared to 28.6 percent in the quarter ended March 31, 2013.    

Research and development expenses were $29.5 million for the quarter, or 7.4 percent of revenue.  R&D expenses decreased by 5 percent (a 7 percent increase on a constant currency basis) compared to the quarter ended March 31, 2013.  R&D expenses were favorably impacted by the depreciation of the Australian dollar against the U.S. dollar.

ResMed amortized acquired intangibles of $2.5 million ($1.9 million, net of tax) during the quarter.  Stock-based compensation costs incurred during the quarter of $11.2 million ($8.1 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the company's employee stock purchase plan.  

For the nine months ended March 31, 2014, revenue was $1,139.8 million, an increase of 4 percent over the nine months ended March 31, 2013 (a 3 percent increase on a constant currency basis).  For the nine months, net income was $257.5 million, an increase of 10 percent compared to the nine months ended March 31, 2013.  Diluted earnings per share for the nine months were $1.78 per diluted share, an increase of 11 percent compared to the nine months ended March 31, 2013.

In the third quarter of fiscal year 2014, revenue outside the Americas was $181.6 million, an increase of 8 percent over the prior year's quarter.  In constant currency terms, revenue outside the Americas increased by 6 percent. Revenue in the Americas, at $216.1 million, remained flat compared to the prior year's quarter of $215.2 million. Operating profit for the third quarter grew to $104.7 million, cash flow from operations was $101.1 million, while gross margin was 63.3 percent, all demonstrating robust operating performance. During the quarter, the company also repurchased 1.6 million shares at a cost of $72.5 million, as part of its ongoing capital management program.

"We are pleased with our third quarter results in the face of challenging market conditions, particularly in the U.S.," said ResMed chief executive officer Michael "Mick" Farrell.  "Our Americas business showed encouraging trends and we continue to benefit from our globally diversified business, with constant currency revenue growth of 6 percent in combined Europe and Asia-Pacific businesses for the quarter. In particular, our European results were strong across the board, with most countries showing solid growth."

Highlighting ResMed's new products, Farrell continued, "At the beginning of the third quarter, we launched our new nasal pillows interface, the AirFitP10, in the U.S., and it's been very well received. In addition to its brisk adoption, we received global validation of our innovation and design excellence when the AirFit P10 won the prestigious 2014 Red Dot Product Design award, the world's largest design competition. Sales of the AirFit P10 have just begun in Europe and Asia-Pacific.  Earlier this week, ResMed announced the U.S. launch of two additional new masks to kick-start the fourth quarter of its fiscal year: the AirFit F10, the lightest full-face mask on the market; and the AirFit N10, a new patient-preferred nasal mask. Both masks will be launched soon in other major countries.

"On the flow generator side, we are now in the full product launch phase of our new respiratory care platform in Europe.  The Astral™ is our new generation of life support ventilators. Its competitive advantages are its small size and long battery life, making it an ultra-portable system. It showcases ResMed's growing strength in software design, with patient-friendly set-up and operation. These features allow adult and pediatric patients, who would otherwise be hospitalized, to be safely treated outside the hospital for various chronic diseases. The Astral platform also won a prestigious Red Dot Product Design award, and received positive reaction from patients, providers, and physicians during its controlled product launch in Europe during the third quarter.  We are now ready for full commercial launch of this respiratory care platform in Europe and Asia-Pacific, and our U.S. launch is pending FDA clearance, which we anticipate later this year," Farrell said.

Farrell concluded, "We were also particularly pleased with our bottom-line results this quarter.  Our operating profit, net income, and earnings per share all grew year-over-year at a faster pace than our revenue, with earnings per share up 9 percent.  We expect to continue to take advantage of ongoing growth opportunities in sleep-disordered breathing, chronic obstructive pulmonary disease, and cardiorespiratory diseases.  Our offerings improve patient outcomes and quality of life, while reducing costs for global healthcare systems."

The ResMed board of directors has today declared a quarterly dividend of $0.25 per share, which will have a record date of May 20, 2014, and be payable on June 17, 2014. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.  Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be May 14, 2014 for CDI holders and May 16, 2014 for common stock holders. As a result of these differences, ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 14, 2014 through May 20, 2014, inclusive. 

About ResMed

ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results.  Individuals wishing to access the conference call may do so via ResMed's website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference passcode no. 36956405.   Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast.  The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks.  A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 36956405.

For Investors: Further information can be obtained by contacting David Pendarvis at ResMed Inc., San Diego, at (858) 836-5000; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the company's multilingual website at www.resmed.com

For News Media: Contact Gretchen Griswold, director of Global Corporate Communications at (858) 836-6789.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings,  expenses, new product development, new product launches and new markets for its products --  are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

 

ResMed Inc and Subsidiaries

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)



Three Months Ended

March 31,

Nine months Ended

March 31,


2014

2013

2014

2013






Net revenue

$397,758

$383,581

$1,139,762

$1,099,850

Cost of sales

145,970

144,132

411,234

419,041

Gross profit

251,788

239,449

728,528

680,809






Operating expenses:





Selling, general and administrative

115,101

109,628

328,172

315,745

Research and development

29,530

31,189

86,430

88,735

Amortization of acquired intangible assets

2,459

2,533

7,325

7,671

Total operating expenses

147,090

143,350

421,927

412,151

Income from operations

104,698

96,099

306,601

268,658






Other income (expenses), net:





Interest income (expense), net

6,015

8,078

19,182

25,047

Other, net

2,199

3,815

(1,340)

3,587

Total other income (expenses), net

8,214

11,893

17,842

28,634






Income before income taxes

112,912

107,992

324,443

297,292

Income taxes

22,943

23,079

66,908

63,172

Net income

$89,969

$84,913

$257,535

$234,120






Basic earnings per share

$0.64

$0.59

$1.82

$1.64

Diluted earnings per share

$0.63

$0.58

$1.78

$1.60






Basic shares outstanding

140,959

143,293

141,774

143,049

Diluted shares outstanding

143,375

146,643

144,758

146,479






 


ResMed Inc And Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited - In thousands)



March 31,

June 30,


2014

2013

Assets



Current assets:



Cash and cash equivalents

$938,563

$876,048

Accounts receivable, net

337,572

318,349

Inventories

164,888

145,847

Prepayments, deferred income taxes and other current assets

122,879

108,605

Total current assets

1,563,902

1,448,849

Property, plant and equipment, net

429,049

411,433

Goodwill

290,785

274,829

Other intangibles

46,153

49,639

Deferred income taxes and other non-current assets

34,677

25,971

Total non-current assets

800,664

761,872

Total assets

$2,364,566

$2,210,721

Liabilities and Stockholders' Equity



Current liabilities:



Accounts payable

$55,483

$60,688

Accrued expenses

142,082

137,674

Deferred revenue

42,182

44,953

Income taxes payable

6,353

30,090

Deferred income taxes

774

627

Current portion of long-term debt

18

300,017

Total current liabilities

246,892

574,049

Non-current liabilities:



Deferred income taxes

10,081

9,895

Deferred revenue

15,585

11,928

Income taxes payable

5,318

3,564

Non-current portion of long-term debt

395,785

769

Total non-current liabilities

426,769

26,156

Total liabilities

673,661

600,205

Stockholders' Equity:



Common stock

561

568

Additional paid-in capital

1,084,502

1,025,064

Retained earnings

1,727,789

1,576,641

Treasury stock

(1,251,482)

(1,083,845)

Accumulated other comprehensive income

129,535

92,088

Total stockholders' equity

$1,690,905

$1,610,516




Total liabilities and stockholders' equity

$2,364,566

$2,210,721




 

Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

SOURCE ResMed Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Application transformation and DevOps practices are two sides of the same coin. Enterprises that want to capture value faster, need to deliver value faster – time value of money principle. To do that enterprises need to build cloud-native apps as microservices by empowering teams to build, ship, and run in production. In his session at @DevOpsSummit at 19th Cloud Expo, Neil Gehani, senior product manager at HPE, discussed what every business should plan for how to structure their teams to delive...
"We analyze the video streaming experience. We are gathering the user behavior in real time from the user devices and we analyze how users experience the video streaming," explained Eric Kim, Founder and CEO at Streamlyzer, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Get deep visibility into the performance of your databases and expert advice for performance optimization and tuning. You can't get application performance without database performance. Give everyone on the team a comprehensive view of how every aspect of the system affects performance across SQL database operations, host server and OS, virtualization resources and storage I/O. Quickly find bottlenecks and troubleshoot complex problems.
SYS-CON Events announced today that Fusion, a leading provider of cloud services, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Fusion, a leading provider of integrated cloud solutions to small, medium and large businesses, is the industry’s single source for the cloud. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including clou...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
"MathFreeOn.com is a line coding platform for engineers and scientists. When they want to solve an engineering problem and they have to use software - they have to pay a lot of money for licenses - but with MathFreeOn you don't have to pay a lot of money. Just go to our site and write the code and you can check the result right away," explained Simon Lee, CMO of MathFreeOn, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Cla...
SYS-CON Events announced today that Dataloop.IO, an innovator in cloud IT-monitoring whose products help organizations save time and money, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Dataloop.IO is an emerging software company on the cutting edge of major IT-infrastructure trends including cloud computing and microservices. The company, founded in the UK but now based in San Fran...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
"This is specifically designed to accommodate some of the needs for high availability and failover in a network managed system for the major Korean corporations," stated Thomas Masters, Managing Director at InfranicsUSA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.